Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans - PubMed (original) (raw)
. 2012 Jan 29;18(2):274-80.
doi: 10.1038/nm.2612.
Chris K F Li, Cecilia S C Chui, Arthur K Y Huang, Molly Perkins, Julia C Liebner, Rob Lambkin-Williams, Anthony Gilbert, John Oxford, Ben Nicholas, Karl J Staples, Tao Dong, Daniel C Douek, Andrew J McMichael, Xiao-Ning Xu
Affiliations
- PMID: 22286307
- DOI: 10.1038/nm.2612
Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans
Tom M Wilkinson et al. Nat Med. 2012.
Abstract
Protective immunity against influenza virus infection is mediated by neutralizing antibodies, but the precise role of T cells in human influenza immunity is uncertain. We conducted influenza infection studies in healthy volunteers with no detectable antibodies to the challenge viruses H3N2 or H1N1. We mapped T cell responses to influenza before and during infection. We found a large increase in influenza-specific T cell responses by day 7, when virus was completely cleared from nasal samples and serum antibodies were still undetectable. Preexisting CD4+, but not CD8+, T cells responding to influenza internal proteins were associated with lower virus shedding and less severe illness. These CD4+ cells also responded to pandemic H1N1 (A/CA/07/2009) peptides and showed evidence of cytotoxic activity. These cells are an important statistical correlate of homotypic and heterotypic response and may limit severity of influenza infection by new strains in the absence of specific antibody responses. Our results provide information that may aid the design of future vaccines against emerging influenza strains.
Comment in
- CD4+ T cells limit the damage in influenza.
Kelso A. Kelso A. Nat Med. 2012 Feb 6;18(2):200-2. doi: 10.1038/nm.2654. Nat Med. 2012. PMID: 22310682 No abstract available.
Similar articles
- Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells.
Hillaire MLB, van Trierum SE, Kreijtz JHCM, Bodewes R, Geelhoed-Mieras MM, Nieuwkoop NJ, Fouchier RAM, Kuiken T, Osterhaus ADME, Rimmelzwaan GF. Hillaire MLB, et al. J Gen Virol. 2011 Oct;92(Pt 10):2339-2349. doi: 10.1099/vir.0.033076-0. Epub 2011 Jun 8. J Gen Virol. 2011. PMID: 21653752 - Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.
Desheva YA, Smolonogina TA, Donina SA, Rudenko LG. Desheva YA, et al. BMC Res Notes. 2015 Apr 10;8:136. doi: 10.1186/s13104-015-1086-z. BMC Res Notes. 2015. PMID: 25889924 Free PMC article. - Age-related changes in memory and effector T cells responding to influenza A/H3N2 and pandemic A/H1N1 strains in humans.
Zhou X, McElhaney JE. Zhou X, et al. Vaccine. 2011 Mar 3;29(11):2169-77. doi: 10.1016/j.vaccine.2010.12.029. Vaccine. 2011. PMID: 21353149 Free PMC article. - Recalling the Future: Immunological Memory Toward Unpredictable Influenza Viruses.
Auladell M, Jia X, Hensen L, Chua B, Fox A, Nguyen THO, Doherty PC, Kedzierska K. Auladell M, et al. Front Immunol. 2019 Jul 2;10:1400. doi: 10.3389/fimmu.2019.01400. eCollection 2019. Front Immunol. 2019. PMID: 31312199 Free PMC article. Review. - Virus-specific T cells as correlate of (cross-)protective immunity against influenza.
Altenburg AF, Rimmelzwaan GF, de Vries RD. Altenburg AF, et al. Vaccine. 2015 Jan 15;33(4):500-6. doi: 10.1016/j.vaccine.2014.11.054. Epub 2014 Dec 9. Vaccine. 2015. PMID: 25498210 Review.
Cited by
- Vaccination of aged mice with adjuvanted recombinant influenza nucleoprotein enhances protective immunity.
Cookenham T, Lanzer KG, Gage E, Lorenzo EC, Carter D, Coler RN, Baldwin SL, Haynes L, Reiley WW, Blackman MA. Cookenham T, et al. Vaccine. 2020 Jul 14;38(33):5256-5267. doi: 10.1016/j.vaccine.2020.05.085. Epub 2020 Jun 12. Vaccine. 2020. PMID: 32540272 Free PMC article. - Characterisation of a wild-type influenza (A/H1N1) virus strain as an experimental challenge agent in humans.
Watson JM, Francis JN, Mesens S, Faiman GA, Makin J, Patriarca P, Treanor JJ, Georges B, Bunce CJ. Watson JM, et al. Virol J. 2015 Feb 3;12:13. doi: 10.1186/s12985-015-0240-5. Virol J. 2015. PMID: 25645025 Free PMC article. - Meeting Report From "Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID-19 Pandemic".
Krammer F, Katz JM, Engelhardt OG, Post DJ, Roberts PC, Sullivan SG, Tompkins SM, Chiu C, Schultz-Cherry S, Cox RJ. Krammer F, et al. Influenza Other Respir Viruses. 2024 Oct;18(10):e13314. doi: 10.1111/irv.13314. Influenza Other Respir Viruses. 2024. PMID: 39380156 Free PMC article. - Use it or lose it: establishment and persistence of T cell memory.
Kedzierska K, Valkenburg SA, Doherty PC, Davenport MP, Venturi V. Kedzierska K, et al. Front Immunol. 2012 Nov 27;3:357. doi: 10.3389/fimmu.2012.00357. eCollection 2012. Front Immunol. 2012. PMID: 23230439 Free PMC article. - The expression of B & T cell activation markers in children's tonsils following live attenuated influenza vaccine.
Panapasa JA, Cox RJ, Mohn KG, Aqrawi LA, Brokstad KA. Panapasa JA, et al. Hum Vaccin Immunother. 2015;11(7):1663-72. doi: 10.1080/21645515.2015.1032486. Hum Vaccin Immunother. 2015. PMID: 26148331 Free PMC article. Clinical Trial.
References
- J Virol. 1983 Oct;48(1):52-60 - PubMed
- J Virol. 1996 Sep;70(9):5799-806 - PubMed
- J Immunol. 2002 Jun 1;168(11):5954-8 - PubMed
- J Immunol. 2008 Feb 1;180(3):1758-68 - PubMed
- N Engl J Med. 2004 Jan 15;350(3):218-20 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- G0600520/MRC_/Medical Research Council/United Kingdom
- MC_U137884177/MRC_/Medical Research Council/United Kingdom
- G1001047/MRC_/Medical Research Council/United Kingdom
- MC_U137881015/MRC_/Medical Research Council/United Kingdom
- G1001046/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials